Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H27NO2 |
Molecular Weight | 337.4553 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCCCCCNC1C2=CC=CC=C2CCC3=C1C=CC=C3
InChI
InChIKey=ONNOFKFOZAJDHT-UHFFFAOYSA-N
InChI=1S/C22H27NO2/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25)
Amineptine is a selective inhibitor of dopamine reuptake. The drug was developed in France and was marketed for the treatment of depressive disorders under the name Survector among the others. Amineptine was withdrawn from the French market in 1999 because of abuse and drug dependence and because of its hepatic (cholestatic injuries) and cutaneous (acne) adverse effects.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21584062 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Survector Approved UseSurvector 100mg tablet is used in the treatment of depression. Launch Date1977 |
PubMed
Title | Date | PubMed |
---|---|---|
[Amineptine-induced cholestatic hepatitis. 5 cases (author's transl)]. | 1980 Dec 20 |
|
[Hepatitis caused by amineptine : a case with reintroduction of the drug]. | 1981 Nov |
|
[Effects of thymo-analeptics and acceptability of amineptin compared to those of imipramine]. | 1982 |
|
[Amineptin-induced hepatitis: differential diagnosis of biliary microlithiasis]. | 1982 Nov |
|
[Iatrogenic acne caused by amineptin (Survector). Apropos of 8 cases]. | 1988 |
|
[Acneiform eruption induced by amineptin (Survector)]. | 1989 |
|
[Amineptin dependence and iatrogenic acne. Review of the literature apropos of a case]. | 1991 Dec |
|
The serotonin syndrome. | 1992 Oct |
|
[Acne induced by amineptin: adnexal toxiderma]. | 1996 |
|
Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study. | 1997 Sep |
|
WHO Expert Committee on Drug Dependence. Thirty-second report. | 2001 |
|
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. | 2001 |
|
Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme. | 2001 Mar |
|
Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs. | 2002 Dec |
|
[Does addiction to antidepressants exist? About a case of one addiction to tianeptine]. | 2003 Sep-Oct |
|
Spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides through ion-pair formation with molybdenum and thiocyanate. | 2006 Dec |
|
Antidepressants for anorexia nervosa. | 2006 Jan 25 |
|
Spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides through ion-pair formation using methyl orange and bromocresol green reagents. | 2006 Sep |
|
Utility of 7,7,8,8-tetracyanoquinodimethane charge transfer reagent for the spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides. | 2007 Dec 31 |
|
Update on the management of symptoms in schizophrenia: focus on amisulpride. | 2009 |
|
Treatment for amphetamine withdrawal. | 2009 Apr 15 |
|
Spectroscopic and electrochemical analysis of psychotropic drugs. | 2009 Jan |
|
Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. | 2009 Jun |
|
A new strategy for antidepressant prescription. | 2010 |
|
Management of anorexia and bulimia nervosa: An evidence-based review. | 2010 Apr |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Research on antidepressants in India. | 2010 Jan |
|
Molecular biology research in neuropsychiatry: India's contribution. | 2010 Jan |
Patents
Sample Use Guides
Patients receive 200 mg of amineptine (survector) daily, in two divided doses at 8 A.M. and 12 noon for 6 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1797329
Rat neurones were treated with 300 nM-30uM of amineptine. Amineptine (1-30uM) decreased spontaneous firing and slightly hyperpolarized the membrane potential. At 300 nM-30uM amineptine increased the amplitude and duration of responses to exogenously applied dopamine.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
1219
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
||
|
WHO-VATC |
QN06AA19
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
||
|
WHO-ATC |
N06AA19
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID1048831
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
100000087225
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
17698
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | RxNorm | ||
|
3998
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
AMINEPTINE
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
C011597
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
m1673
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | Merck Index | ||
|
32499
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
SUB05435MIG
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
C74142
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
260-818-0
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
34870
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
27T1I13L6G
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
161
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
CHEMBL418995
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
57574-09-1
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY | |||
|
DB04836
Created by
admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)